Advanced Micro Devices (AMD) could potentially outperform
Nvidia in 2025. The company is investing in
Absci for AI-driven drug discovery and is partnering with
Dell to develop new Pro Devices powered by Ryzen AI PRO processors for enhanced business productivity. With an upgrade from S&P Global to an 'A' rating due to strong market share and
AI growth, the company has a bright outlook. However, the postulations are not unaccompanied by critiques, with
AMD shares plunging 5% as analysts cut rating on AI concerns, and there are concerns about increased competitive pressure from Goldman Sachs' downgrade of AMD. Furthermore, remarks from HSBC about the reduction in AMD's rating and doubts about potential AI revenue have set off alerts. A more innovative leap comes from AMD's exploration into the life sciences sector. This move is viewed as an attempt to reverse the company's recent stock decline. There are also anticipation for February's 28th available options for AMD and many are keenly observing the company's AI revenue outlook.
Advanced Micro Devices AMD News Analytics from Tue, 12 Nov 2024 08:00:00 GMT to Sat, 11 Jan 2025 23:10:59 GMT -
Rating -2
- Innovation 8
- Rumor -3
